Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
224 hedge funds and large institutions have $2.68B invested in Amicus Therapeutics in 2019 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 86 increasing their positions, 57 reducing their positions, and 26 closing their positions.
92% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 26
65% more call options, than puts
Call options by funds: $9.49M | Put options by funds: $5.74M
51% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 57
22% more capital invested
Capital invested by funds: $2.2B → $2.68B (+$482M)
9% more funds holding
Funds holding: 205 → 224 (+19)
0.35% more ownership
Funds ownership: 107.63% → 107.98% (+0.35%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$27.4M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$22.2M |
| 3 |
Morgan Stanley
New York
|
+$18.8M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$18.3M |
| 5 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$36.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$24.9M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$16.9M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$15.6M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$13.3M |
FOLD Hedge Fund Activity: Q4 2019 in Review
224 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2019, worth a combined $2.68B — up 22% from $2.2B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new FOLD positions and 26 closed out — a net gain of 24 holders — while 86 added to existing stakes and 57 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $27.4M. The largest seller was Deutsche Bank, cutting an estimated $36.7M.
- 224 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2019, up from 205 in Q3 2019.
- Funds reported $2.68B of Amicus Therapeutics stock for Q4 2019, up 22% quarter-over-quarter.
- 50 funds opened new Amicus Therapeutics positions in Q4 2019 and 26 closed out, a net change of +24 holders.
- The largest Amicus Therapeutics buyer in Q4 2019 was JP Morgan Chase, an estimated $27.4M added.
- The largest Amicus Therapeutics seller in Q4 2019 was Deutsche Bank, an estimated $36.7M sold.
Based on aggregated 13F filings for Q4 2019.